Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Zamtocabtagene autoleucel |
Trade Name | |
Synonyms | MBCART2019.1|MB CART2019.1|MB-CART2019.1 |
Drug Descriptions |
Zamtocabtagene autoleucel (MB-CART2019.1) are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both CD20 and CD19, potentially resulting in antitumor activity (Blood (2020) 136 (Supplement 1): 48). |
DrugClasses | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 |
CAS Registry Number | NA |
NCIT ID | C180596 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Zamtocabtagene autoleucel | Zamtocabtagene autoleucel | 0 | 1 |